Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma
Endocrine-Related Cancer, 06/05/09
Durante C et al. - In a study to evaluate the long-term outcome and prognostic factors for survival in pts with distant metastases from gastroenteropancreatic well-differentiated endocrine carcinoma (GEP WDEC), this study enables the stratification of metastatic GEP WDEC pts into distinct risk groups. These risk categories can be used to tailor therapeutic approaches and to design and interpret clinical trials.
Methods- Long-term outcome and prognostic factors for survival were evaluated in 118 pts with distant metastases from GEP WDEC.
- Inclusion criteria included pathological review by a single pathologist according to WHO criteria, absence of previous therapy apart from surgery, complete morphological evaluation within 3 mos including somatostatin receptor scintigraphy, and follow-up at Gustave-Roussy Institute until death or study's end.
- Clinical, biological marker, and pathological parameters were analyzed in univariate and multivariate statistical models.
- Survival after the first complete imaging work-up of the metastatic disease was determined using Kaplan–Meier method.
- Survival for 5 yrs after diagnosis of metastatic disease was 54%.
- In multivariate analysis, age, number of liver metastases, tumor slope, and initial surgery were predictive of survival.
- 5-yr survival was 100%, 91%, 62%, and 9% when pts had 0, 1, 2, 3, or more poor prognostic features, respectively.
Today in Endocrine Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer
Thyroid, 10/30/09
Thyroid lymphoma and airway obstruction – is there a rationale for surgical management?
International Journal of Clinical Practice, 10/19/09
Thyroid Cancer in Systemic Lupus Erythematosus: A Case-Control Study
Journal of Clinical Endocrinology and Metabolism, 11/12/09
Today in GI Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer
Journal of Clinical Oncology, 11/02/09
Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer
Journal of Clinical Oncology, 10/29/09
Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer
Journal of Clinical Oncology, 11/03/09
Today in Hepatobiliary/Pancreas...keeping you current
Receive free subspecialty "5-minute updates" via email
Surgical management of hepatocellular carcinoma: Is the jury still out
Surgical Oncology, 11/05/09
Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials
British Journal of Cancer, 11/13/09
Macronutrients, fatty acids, cholesterol and pancreatic cancer
European Journal of Cancer, 10/27/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


